Table 7. Relationship between miRNAs polymorphism and prognosis of gastric cancer in different subgroups.

Clinical pathological parameters	Genotype (death/total)			Dominant model		Recessive model
	wild type	hybrid type	mutation type	P	HR	P	HR
pri-let7e rs8111742
Age
≤60	19/82	18/71	3/9	0.670	1.15(0.62–2.13)	0.389	1.51(0.59–3.86)
>60	29/100	16/72	2/15	0.854	0.95(0.54–1.67)	0.608	1.27(0.51–3.22)
Gender
Male	36/131	25/109	1/14	0.902	0.97(0.59–1.59)	0.612	1.24(0.54–2.89)
Female	12/53	10/39	4/10	0.539	1.27(0.59–2.76)	0.380	1.61(0.56–4.69)
Borrmann type
Borrmann I–II	13/37	10/31	0/5	0.140	0.53(0.23–1.23)	0.464	1.58(0.47–5.32)
Borrmann III–IV	35/128	23/99	5/18	0.230	1.35(0.83–2.20)	0.450	1.35(0.62–2.96)
Lauren type
Intestinal type	14/69	10/53	2/7	0.512	0.75(0.32–1.76)	0.435	0.05(0.00–105.98)
Diffuse type	32/112	24/93	3/17	0.485	1.20(0.72–2.01)	0.079	1.84(0.93–3.62)
TNM staging
I–II	20/91	11/75	0/10	0.052	0.22(0.05–1.01)	0.510	0.04(0.00–484.52)
II–IV	28/93	24/73	5/14	0.573	1.14(0.73–1.79)	0.298	1.42(0.73–2.77)
Depth of invasion	0/43	1/34	0/7	0.591	0.52(0.05–5.71)	0.653	NA
T1 + T2	32/102	25/87	5/13	0.715	1.08(0.71–1.65)	0.071	1.84(0.95–3.56)
T3 + T4
Lymph node metastasis
Positive	38/110	32/88	5/15	0.610	1.12(0.72–1.76)	0.593	1.20(0.62–2.33)
Negative	10/74	2/59	0/9	0.141	0.38(0.10–1.39)	0.611	NA
pri-miR-365b rs121224
Age
≤60	13/43	23/83	3/31	0.522	0.82(0.45–1.51)	0.066	0.33(0.10–1.08)
>60	15/48	26/104	6/30	0.473	0.79(0.41–1.51)	0.457	0.72(0.31–1.70)
Gender
Male	20/63	36/142	6/43	0.246	0.73(0.43–1.24)	0.087	0.48(0.21–1.11)
Female	9/32	13/48	3/18	0.930	0.96(0.43–2.19)	0.448	0.63(0.19–2.10)
Borrmann type
Borrmann I–II	10/25	11/39	2/9	0.172	0.56(0.25–1.28)	0.703	0.75(0.18–3.22)
Borrmann III–IV	18/59	37/129	7/47	0.686	0.90(0.53–1.53)	0.042	0.44(0.20–0.97)
Lauren type
Intestinal type	9/38	15/59	2/30	0.626	0.82(0.36–1.85)	0.031	0.20(0.05–0.86)
Diffuse type	18/54	34/130	6/30	0.486	0.82(0.47–1.43)	0.577	0.79(0.34–1.83)
TNM staging
I–II	13/52	15/83	3/34	0.065	0.34(0.11–1.07)	0.296	0.34(0.04–2.60)
III–IV	16/43	34/107	6/27	0.917	1.03(0.63–1.68)	0.458	0.76(0.36–1.58)
Depth of invasion
T1 + T2	1/21	0/46	0/17	0.203	0.21(0.02–2.32)	0.607	NA
T3 + T4	17/46	37/109	7/37	0.428	0.83(0.53–1.31)	0.088	0.55(0.28–1.10)
Lymph node metastasis
Positive	22/54	44/119	8/34	0.833	0.95(0.58–1.55)	0.164	0.59(0.29–1.24)
Negative	6/40	5/71	1/27	0.067	0.35(0.11–1.08)	0.346	0.37(0.05–2.89)
pri-mir4795 rs1002765
Age
≤60	14/64	21/79	5/19	0.952	1.02(0.53–1.95)	0.771	0.87(0.34–2.22)
>60	17/58	19/96	11/32	0.258	0.71(0.39–1.28)	0.351	1.38(0.70–2.70)
Gender
Male	23/95	28/123	11/35	0.528	0.85(0.51–1.42)	0.531	1.23(0.64–2.36)
Female	42246	13/55	5/17	0.594	0.80(0.35–1.84)	0.963	0.98(0.37–2.60)
Borrmann type
Borrmann I–II	7/17	10/41	6/15	0.711	0.91(0.55–1.50)	0.337	1.58(0.62–4.00)
Borrmann III–IV	23/91	30/120	10/33	0.509	0.74(0.31–1.80)	0.936	1.03(0.52–2.02)
Lauren type
Intestinal type	9/45	13/64	4/19	0.693	0.85(0.37–1.92)	0.851	0.90(0.31–2.63)
Diffuse type	22/79	25/110	12/33	0.279	0.75(0.44–1.27)	0.411	1.30(0.69–2.45)
TNM staging
I–II	7/55	16/92	8/28	0.254	2.42(0.53–11.05)	0.417	1.72(0.46–6.38)
III–IV	24/70	25/86	8/24	0.078	0.66(0.41–1.05)	0.897	1.04(0.57–1.89)
Depth of invasion
T1 + T2	1/29	0/44	0/11	0.211	0.22(0.02–2.38)	0.626	NA
T3 + T4	23/77	30/98	9/26	0.598	0.89(0.57–1.39)	0.507	1.20(0.70–2.07)
Lymph node metastasis
Positive	29/75	33/107	13/31	0.086	0.67(0.42–1.06)	0.734	1.11(0.61–2.01)
Negative	2/50	7/70	3/21	0.232	2.53(0.55–11.54)	0.503	1.57(0.42–5.81)

HR, hazard rate; NA, not avalable.